Medical Science Liaisons are meant to be the scientific bridge between pharma and the oncologists who prescribe their therapies — but our latest Market Signal reveals a widening gap between what oncologists want from these interactions and what they actually receive. Engagement isn’t the problem: most oncologists see four or more MSLs every six months. The real limiting factor is relevance, with 71% citing generic, scripted visits as the top reason an interaction feels like a poor use of their time. And the stakes are high — 63% say MSL conversations directly shape their consideration of new therapies.
This Market Signal turns candid oncologist feedback into a clear blueprint for what separates elite MSL programs from average ones. You’ll see exactly what oncologists want more of — specialty-specific content (88%), more detailed and accurate answers (76%), and faster, more reliable follow-up — and why these gaps are structural, fixable issues rooted in training, coverage models, and KPI design. You’ll also discover which companies oncologists name as getting it right — AstraZeneca, Roche/Genentech, and Novartis — and the specific behaviors that earn that recognition: scientific breadth beyond the label, genuine access facilitation, and practice-level customization. The behaviors that define top-performing MSL teams are codifiable, trainable, and worth acting on now. Download the report now.
Download our ebook, “The Evolution of Market Research in Healthcare,” to discover the trends redefining the field and how Konovo is helping companies turn insight into action.
